Aggrastat (tirofiban) / Correvio, Medicure - LARVOL DELTA

ADJUVANT: Intravenous Tirofiban Versus Thrombolysis Before Mechanical Thrombectomy in Stroke (clinicaltrials.gov) - P2/3 | N=1014 | Completed | Sponsor: Xinqiao Hospital of Chongqing | Recruiting ➔ Completed

Trial completion • Cardiovascular • Ischemic stroke

TEARIAS: The Efficacy and Safety of Tirofiban Enhanced Antiplatelet Therapy in the Treatment of Ruptured Intracranial Aneurysms With Stent (clinicaltrials.gov) - P3 | N=622 | Not yet recruiting | Sponsor: First Affiliated Hospital of Fujian Medical University

New P3 trial • Cardiovascular • Hematological Disorders • Subarachnoid Hemorrhage • Vascular Neurology

An innovative endovascular approach for acute ischemic stroke attributable to ICAS-LVO: the RESCUE (Retrievable stent-Endovascular tirofiban-paSs-ExtraCtion-microgUide-rEscue angioplasty) technique. (PubMed, Front Neurol) - "The RESCUE technique is a safe and effective lesion-specific endovascular strategy for ICAS-LVO, providing superior FPR and shorter procedural time compared with the conventional Solumbra technique, without increasing safety concerns. Larger-scale multicenter investigations are needed to confirm these results."

Clinical • Journal • Atherosclerosis • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Thrombosis

The role of intravenous tirofiban in patients undergoing endovascular treatment for acute intracranial atherosclerotic occlusion. (PubMed, J Stroke Cerebrovasc Dis) - No abstract available

Journal • Atherosclerosis

The Safety of Early Intravenous Tirofiban in Acute Ischemic Stroke: A Meta-analysis of Randomized Controlled Trials. (PubMed, Cerebrovasc Dis) - "Early intravenous tirofiban is associated with a significantly increased risk of any intracranial hemorrhage. Although no statistically significant increases in symptomatic intracranial hemorrhage or mortality were detected, the wide confidence intervals preclude the definitive exclusion of clinically meaningful harm."

Journal • Retrospective data • Review • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Pre-Procedural Intravenous Tirofiban and First-Pass Reperfusion in Anterior-Circulation Thrombectomy: A Meta-Analysis of Randomized Trials Stratified by Atherosclerotic Mechanism (AHA 2026) - "Abstract is embargoed at this time."

Retrospective data • Atherosclerosis

Effect of Intracoronary Recombinant Human Prourokinase on Myocardial Perfusion and Clinical Outcomes in STEMI Patients Undergoing Primary PCI: A Randomized Controlled Trial. (PubMed, Rev Cardiovasc Med) - P=N/A | "In this prospective, single-blind, randomized, controlled clinical trial, 136 ST-segment elevation myocardial infarction (STEMI) patients undergoing emergency percutaneous coronary intervention (PCI) at Anqing Municipal Hospital (August 2021-June 2023) were randomized 1:1:1 to intracoronary rhPro-UK (n = 44), tirofiban (n = 44), or saline groups (n = 48). Intracoronary rhPro-UK administration during emergency PCI in STEMI patients reduces post-reperfusion inflammation and fibrosis, limits infarct size, and improves clinical outcomes. Chinese Clinical Trial Registry (ChiCTR; http://www.chictr.org.cn; Identifier: ChiCTR2100047095)."

Clinical • Clinical data • Journal • Cardiovascular • Fibrosis • Immunology • Myocardial Infarction • Oncology • CXCL8 • IL6 • ST2 • TNFA

Ticagrelor-Aspirin With Thrombolysis by Infarct Patterns in Moderate Ischemic Stroke: TAPIS Subgroup Analysis. (PubMed, Stroke) - P3 | "Early neurological improvement showed significant heterogeneity by infarction pattern (Pinteraction=0.02); the treatment‑by‑pattern interaction for the primary outcome was nominally significant after adjusting for rescue tirofiban use (P=0.04). These hypothesis‑generating findings may inform future trials of diffusion‑weighted imaging infarction pattern as an imaging biomarker to guide antiplatelet therapy in early reperfusion. URL: https://www.clinicaltrials.gov; Unique identifier: NCT06316570."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Impact of Preemptive vs. Conventional Tirofiban Administration on the Outcomes in Acute Branch Atheromatous Disease: A Propensity Score-Weighted Cohort Study. (PubMed, CNS Neurosci Ther) - "Preemptive administration of tirofiban within the initial 72 h significantly improves 90-day neurological outcomes and reduces hospital stay length in patients with BAD-related stroke."

Clinical • Journal • Retrospective data • Cardiovascular

Rescue Tirofiban for Early Neurological Deterioration After Tenecteplase in Capsular Warning Syndrome. (PubMed, J Clin Neurol) - No abstract available

Journal

Stent-assisted coiling for ruptured anterior choroidal artery aneurysms: A retrospective observational study evaluating safety, efficacy, and antiplatelet strategies. (PubMed, Medicine (Baltimore)) - "However, given the small sample size and exploratory nature of this study, these findings should be considered hypothesis-generating and require confirmation in larger prospective cohorts. Both DAPT and tirofiban appear to be feasible antiplatelet strategies based on the limited data available."

Journal • Observational data • Retrospective data • Cardiovascular • Hematological Disorders • Thrombosis • Vascular Neurology

A protective device for the pathological process of graft vein restenosis after CABG (ESC 2026) - "Tirofiban is incorporated to prevent thrombosis, rapamycin to inhibit intimal hyperplasia, and rosuvastatin to suppress the progression of atherosclerosis.MethodsTransmission electron microscopy (TEM) was used to observe the physical morphology of the device...Panels B and C show the CCK-8 and hemolysis test results, respectively. Together, these findings demonstrate the effectiveness and safety of the device.ConclusionsWe have developed a safe and effective protective device targeting the pathological process of vein graft restenosis after CABG."

Atherosclerosis • Cardiovascular • Coronary Artery Disease • Heart Failure • Thrombosis

Tirofiban for Branch Atheromatous Disease-End of the Line or New Opportunity? (PubMed, JAMA Neurol) - No abstract available

Journal

Tirofiban for Branch Atheromatous Disease-Related Stroke: The STRATEGY Randomized Clinical Trial. (PubMed, JAMA Neurol) - P4 | "This study found that in patients with BAD-related stroke, intravenous tirofiban combined with aspirin did not significantly reduce the risk of END or stroke compared with aspirin alone, nor was it associated with an increased risk of moderate or severe bleeding. ClinicalTrials.gov Identifier: NCT05310968."

Clinical • Journal • Cardiovascular • Ischemic stroke

In AIS with inadequate response to tenecteplase, tirofiban vs. placebo increased excellent functional outcome rate at 90 d. (PubMed, Ann Intern Med) - "Emergency Med: [Formula: see text] GIM/FP/GP: [Formula: see text] Neurology: [Formula: see text]."

Journal

Early antiplatelet therapy was associated with reduced neurological deterioration in stroke patients treated with intravenous thrombolysis. (PubMed, Brain Circ) - "Early tirofiban therapy following IVT was associated with reduced END without increased bleeding risk. Specific patient subgroups may potentially benefit from early antiplatelet therapy, further confirmation is needed."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke

Comparison of clinical efficacy between argatroban and tirofiban in patients with atherosclerotic cerebral infarction complicated by early neurological deterioration. (PubMed, Front Pharmacol) - "No statistically significant differences were detected in overall efficacy or safety outcomes between argatroban and tirofiban in patients with END after atherosclerosis-related ischemic stroke. Subgroup findings suggest that treatment effects may vary according to stroke subtype, highlighting the need for further prospective studies to explore mechanism-based, individualized antithrombotic strategies."

Journal • Atherosclerosis • Cardiovascular • CNS Disorders • Ischemic stroke

Efficacy and safety of low-dose tirofiban plus dual antiplatelet therapy in acute cerebral infarction beyond the thrombolysis window: a non-randomized trial with preliminary findings. (PubMed, J Thromb Thrombolysis) - "Although the primary outcome did not reach statistical significance, consistent sensitivity analyses support the clinical value of tirofiban. Larger randomized controlled trials are warranted."

Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders

Injectable antiplatelet therapies in acute coronary syndromes: Current status and Emerging Therapies. A position paper of the Task Force of Antithrombotic therapy of the ACVC. (PubMed, Eur Heart J Acute Cardiovasc Care) - "Intravenous aspirin is used widely in patients with ACS, while the absorption of oral P2Y12 inhibitors is often delayed, and the intravenous P2Y12 inhibitor cangrelor can achieve almost complete platelet inhibition within minutes. While use of the glycoprotein IIb/IIIa inhibitors (GPI) eptifibatide and tirofiban is decreasing, typically reserved for thrombotic complications or no reflow following PCI, recently zalunfiban, a novel subcutaneously administered GPI has been shown to improve reperfusion before revascularisation in patients with STEMI when given at first medical contact. In this review, we dicuss the rationale and potential benefits of injectable antiplatelet medications, including currently available agents and those in development or being tested in clinical trials. While the benefit of injectable medications on hard clinical endpoints such as major adverse cardiac events remains unclear for an allcomers ACS population, there is emerging data that these..."

Journal • Acute Coronary Syndrome • Anesthesia • Cardiovascular • Myocardial Infarction

Rescue Stenting in Refractory Middle Cerebral Artery Thrombectomy Using Drug-Eluting Stent with Short-Duration Tirofiban Infusion. (PubMed, Neurol India) - "In this descriptive case series of ten patients, a short-duration tirofiban infusion protocol following RIS was feasible and was not associated with a high rate of hemorrhagic complications. These observations are hypothesis-generating and require validation in larger, controlled cohorts."

Journal • Atherosclerosis • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders

Tirofiban-Associated Thrombocytopenia: A Case Report. (PubMed, Cureus) - "Within hours, repeat testing showed a profound fall to 10 × 103/µL, prompting immediate discontinuation of tirofiban, holding aspirin and ticagrelor, hematology consultation, and transfusion of two apheresis platelet units. Early detection, prompt discontinuation, and appropriate supportive care and monitoring are vital to ensure safe recovery and revascularization. Incorporating simple pre-procedure risk stratification, individualizing dosing, and early platelet monitoring may reduce complications while preserving ischemic benefit."

Journal • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Pain • Thrombocytopenia

Tirofiban Combined With Aspirin in Moderate Ischemic Stroke (clinicaltrials.gov) - P4 | N=1168 | Not yet recruiting | Sponsor: Xinqiao Hospital of Chongqing

New P4 trial • Cardiovascular • Ischemic stroke

Adjunctive Tirofiban is not Associated with Reduced 30-Day Ischemic Events in NSTE-ACS Patients with Complex Coronary Lesions After PCI: A Retrospective Observational Cohort Study. (PubMed, Int J Gen Med) - "In this selected non-thrombotic complex-lesion NSTE-ACS cohort, routine adjunctive tirofiban was not associated with improved 30-day ischemic outcomes. Anatomical complexity alone may be insufficient to justify routine "add-on" tirofiban in the absence of thrombotic or bailout indications."

Journal • Observational data • Retrospective data • Acute Coronary Syndrome • Cardiovascular • Thrombosis

Pharmacovigilance analysis of glycoprotein IIb/IIIa inhibitors: A FAERS-based signal detection study. (PubMed, Medicine (Baltimore)) - "This study compares the safety signals of 3 glycoprotein IIb/IIIa inhibitors (GPIs) - tirofiban, abciximab, and eptifibatide - using the US Food and Drug Administration Adverse Event Reporting System, aiming to guide clinical application. Abciximab signals highlight oropharyngeal, otorhinolaryngologic, and urinary tract mucosal surfaces. These findings support pharmacovigilance and warrant validation through prospective studies, with the understanding that all reported associations are based on statistical signals from a spontaneous reporting system and do not establish causality."

Adverse events • Journal • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Pancreatitis • Thrombocytopenia

Real-world experience with RESCUE BT2 tirofiban protocol versus standard care for select patients with acute ischemic stroke at a United States comprehensive stroke center: a single-center retrospective study. (PubMed, Front Neurol) - "The RESCUE BT2 trial demonstrated improved functional outcomes with IV tirofiban versus aspirin, but was conducted predominantly in Han Chinese populations, limiting generalizability to U.S. practice. Implementation of a RESCUE BT2-based IV tirofiban protocol in a U.S. comprehensive stroke center was feasible and demonstrated a favorable safety profile in carefully selected AIS patients. Exploratory associations with improved neurological trajectories warrant prospective evaluation in larger multicenter studies."

Journal • Real-world evidence • Retrospective data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Ischemic stroke • Thrombocytopenia